Ticker: EMMA

Emmaus Life Sciences, Inc. (PINK: EMMA) - quick facts from the Form 10‑Q (Quarter ended June 30, 2025) - Revenues down: Q2 2025 net revenues $2,817,000 vs $5,377,000 in Q2 2024; six months 2025 $5,223,000 vs $7,883,000 in 1H 2024. - Gross profit: Q2 2025 $2,667,000; 1H 2025 $4,848,000. - Net los...

Company Overview: Emmaus Life Sciences, Inc. (PINK: EMMA) operates as a biopharmaceutical company primarily focused on innovative treatments for rare diseases. Its flagship product, Endari®, is designed for reducing complications from sickle cell disease and has seen recent approvals in various M...